Breast Cancer ESMO 2024 Highlights: Key Studies Discussed NATALEE, KEYNOTE 522, DESTINY-Breast12

Breast cancer insights from ESMO 2024Подробнее

Highlights in breast cancer from ESMO 2021Подробнее

2024 ESMO East Highlight VideoПодробнее

Highlights in breast cancer at ESMO 2024: KEYNOTE-522Подробнее

Advancements in metastatic ER+ breast cancer at ESMO Breast 2024Подробнее

Highlights from ESMO Breast 2024: addressing toxicities in new cancer treatmentsПодробнее

DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastasesПодробнее

Update on Keynote 522, the current standard of care for triple negative breast cancer.Подробнее

ESMO 2021 breast cancer highlights: TULIP and KEYNOTE-355Подробнее

NATALEE - Addition of Ribociclib to Endocrine Therapy in Adjuvant Settings - Breast Cancer ESMO 2024Подробнее

ESMO 2024: Highlights and analysisПодробнее

MEDSIR inside ESMO 2024 - Highlights Day 3Подробнее

DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markersПодробнее

HER2+ and PIK3DA-mutated breast cancer updates from ESMO Breast 2024Подробнее

Update from ESMO 24: Breast cancerПодробнее

KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBCПодробнее